Table 4

Univariate comparison of characteristics of patients who were anticoagulated and those who were not anticoagulated

Characteristic

Anticoagulated

(n = 36)

Not anticoagulated

(n = 81)

P


Mean ± SD or n (%)

Mean ± SD or n (%)


Female

34 (94.4%)

71(87.6%)

0.26

Age at CTD diagnosis, years

48.5 ± 14.3

51.1 ± 14.7

0.46

Age at PAH diagnosis*, years

59.7 ± 13.1

62.5 ± 10.6

0.23

Anti-phospholipid antibodies

8 (22.1%)

19 (23.5%)

0.74

Contraindication to anticoagulation

0 (0%)

18 (22.2%)

0.002

WHO functional class

Class I

0 (0%)

9 (11.1%)

Class II

3 (8.3%)

11 (13.6%)

0.09

Class III

32 (88.9%)

56 (69.1%)

Class IV

1 (2.8%)

5 (6.2%)

Baseline 6MWD, m

286.3 ± 116.4

339.5 ± 128.4

0.06

Baseline mRAP, mmHg

7.1 ± 4.3

6.9 ± 4.1

0.85

Baseline mPAP, mmHg

42.0 ± 11.5

33.4 ± 12.0

0.001

Pericardial effusion

9 (25.0%)

5 (6.2%)

0.004

Pulmonary vasodilator therapy

Monotherapy

13 (36.1%)

57 (71.3%)

Sequential monotherapy

2 (5.6%)

10 (12.5%)

< 0.0001

Combination therapy

21 (58.3%)

13 (16.3%)


* date of PAH diagnosis is the date of right heart catheterisation

6MWD, six minute walk distance; CTD, connective tissue disease; ILD, interstitial lung disease; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension; SD, standard deviation; SSc, systemic sclerosis; WHO, World Health Organization

Ngian et al. Arthritis Research & Therapy 2012 14:R213   doi:10.1186/ar4051

Open Data